Epigenome-Wide Association Study (EWAS)
Epigenome-Wide Association Study · Also known as: EWAS, methylome-wide association study, epigenetic association study, DNA methylation association study
An epigenome-wide association study (EWAS) is a hypothesis-free, genome-scale method that systematically tests whether epigenetic marks — predominantly CpG-site DNA methylation — differ between individuals with and without a trait, disease, or exposure. By scanning hundreds of thousands of genomic positions simultaneously, EWAS identifies loci where the epigenome is reproducibly associated with a phenotype, offering a layer of biological regulation that classical GWAS does not capture.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
+7 more
When to use it
Use EWAS when you have a large, well-phenotyped cohort (typically n > 500 for adequate power at genome-wide significance) and wish to identify DNA methylation loci associated with a complex trait, disease, or environmental exposure. It is particularly powerful for studying exposures known to affect the epigenome (smoking, diet, occupational chemicals, early-life adversity) or diseases with an epigenetic component (cancer, metabolic disorders, aging). Do NOT use EWAS as the primary design when your sample is too small (n < 200) — in that case, effect sizes at individual CpGs are rarely detectable without massive multiple-testing penalties. Do not apply EWAS to tissue where the phenotypically relevant cell type cannot be profiled (e.g., brain tissue in a living cohort); surrogate tissues may not carry informative methylation signals for many traits. EWAS alone cannot establish causation; follow-up Mendelian randomisation or longitudinal studies are needed.
Strengths & limitations
- Hypothesis-free, genome-scale discovery that does not require prior knowledge of which CpG sites are relevant.
- Captures an additional regulatory layer (epigenetic) invisible to GWAS, potentially explaining missing heritability.
- Commercially available arrays (450K, EPIC) provide standardised, cost-effective, and reproducible methylation profiling across large cohorts.
- Epigenetic marks are dynamic and reversible, so EWAS findings can point to modifiable biological mechanisms and biomarkers.
- Well-integrated with downstream multi-omics frameworks: EWAS hits can be linked to gene expression (eQTMs), genetic variants (mQTLs), and protein levels.
- Requires large sample sizes (typically n > 500) to achieve genome-wide significance; single-site effect sizes are usually small.
- Tissue-specificity of DNA methylation means that findings in blood may not reflect the causal tissue for many diseases.
- Cell-type heterogeneity in bulk tissue samples is a major confound that deconvolution methods only partially resolve.
- EWAS establishes association, not causation; reverse causation (disease altering methylation) is a persistent interpretive challenge.
- Commercial array probes have known cross-hybridisation issues and do not cover all CpG sites; WGBS is more complete but far more expensive.
Frequently asked
What sample size do I need for an EWAS?
Power calculations suggest that detecting a methylation difference of 2–5% (a typical effect size for complex traits) at genome-wide significance (p < 1 × 10^-7) with 80% power generally requires 500–2000 samples, depending on the trait's epigenetic effect size and the variance in methylation at the locus. For rare or large-effect exposures such as smoking, smaller studies (~200 samples) can detect strong signals, but for subtle trait associations, meta-analyses pooling thousands of participants are the norm.
Should I use beta-values or M-values for the regression?
Both are computed from the same raw intensities. Beta-values (0–1) are biologically interpretable as proportion methylated, making them preferable for reporting and visualisation. M-values (logit of beta) are statistically better behaved — more homoscedastic — and are preferred as the dependent variable in linear regression. The consensus practice is to run regression on M-values and report effect sizes as beta-value differences.
How do I handle the tissue-specificity problem when only blood is available?
Acknowledge that blood methylation is a surrogate for the target tissue and interpret associations cautiously. Use reference datasets (e.g., GTEx methylation, Roadmap Epigenomics) to check whether significant CpGs are co-methylated across tissues. SMR (summary-data-based Mendelian randomisation) linking blood EWAS hits to expression in the target tissue can partially address this. Some traits — particularly immune-related diseases — are genuinely well-studied in blood.
How is EWAS different from GWAS?
GWAS tests associations between fixed DNA sequence variants (SNPs) and a phenotype; SNP genotypes do not change with environment or age. EWAS tests associations between epigenetic marks — primarily DNA methylation — and a phenotype; these marks are malleable and can reflect both genetic and environmental influences. EWAS and GWAS are complementary: mQTL analysis links genetic variants that control methylation levels to GWAS loci, helping to identify causal genes.
What is an mQTL and why does it matter for EWAS interpretation?
A methylation quantitative trait locus (mQTL) is a genetic variant (SNP) that is associated with the methylation level at a nearby or distal CpG site. When a top EWAS CpG site has a known mQTL, that genetic variant can be used in Mendelian randomisation to test whether the methylation difference causally mediates the disease association, or whether the genetic variant independently affects both methylation and disease. Ignoring mQTLs risks mistaking genotype-driven methylation differences for environmentally or disease-driven epigenetic changes.
Sources
- Rakyan, V. K., Down, T. A., Balding, D. J., & Beck, S. (2011). Epigenome-wide association studies for common human diseases. Nature Reviews Genetics, 12(8), 529–541. DOI: 10.1038/nrg3000 ↗
- Pidsley, R., Zotenko, E., Peters, T. J., Lawrence, M. G., Risbridger, G. P., Molloy, P., Van Djik, S., Muhlhausler, B., Stirzaker, C., & Clark, S. J. (2016). Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biology, 17(1), 208. DOI: 10.1186/s13059-016-1066-1 ↗
How to cite this page
ScholarGate. (2026, June 3). Epigenome-Wide Association Study. ScholarGate. https://scholargate.app/en/bioinformatics/epigenome-wide-association-study
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- ChIP-seq Peak CallingBioinformatics↔ compare
- Copy Number Variation AnalysisBioinformatics↔ compare
- eQTL AnalysisBioinformatics↔ compare
- Genome-wide association studyBioinformatics↔ compare
- Pathway Enrichment AnalysisBioinformatics↔ compare